Shares of Medical Marijuana (OTC: MJNA) are ticking higher after the company said its major investment company, AXIM® Biotechnologies (OTC: AXIM), received positive pharmacokinetic (PK) data results on its CanChew Plus® CBD Gum, which will be used in upcoming clinical trials as treatment for irritable bowel syndrome (IBS). The single dose study conducted to determine the concentration of CBD in the blood after chewing one CanChew Plus® Gum for 30 minutes showed positive results for the 30 mg dosage. This data will be used to determine the optimal concentration in the IBS patient trial. AXIM aims to provide a pharmaceutical solution to the IBS market, which is estimated to be worth $1.5 billion by 2023. “AXIM is among just a few companies conducting clinical research on the benefits of cannabinoids. Their research will be the catalyst for change in many sectors of the pharmaceutical industry as we believe that cannabinoid therapeutics has the potential to restructure certain aspects of how medicine will be practiced. We applaud the AXIM team and support continued efforts on this front,” Dr. Stuart Titus, CEO of Medical Marijuana, Inc., stated in the news release.
To view the full press release, visit: http://nnw.fm/6uyRG
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
About AXIM®
AXIM® Biotechnologies, Inc. (OTC: AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit www.AXIMBiotech.com.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of CBDWire (CBDW). NNB keeps you up-to-date on active US Public Companies complementary to CBDW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, CBDW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information, visit https://www.cbdwire.com.
Please see full disclaimers on the CBDWire website: http://nnw.fm/Disclaimer
CBDWire (CBDW)
Denver, CO
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
